Private equity firm Bridgepoint is considering a major acquisition in the healthcare sector, with a potential takeover bid for Advanced Medical Solutions Group (AMS), a specialist surgical products manufacturer listed in London.
Potential Valuation and Share Price Premium
Sky News has learned that Bridgepoint, known for its backing of Burger King UK, is examining an offer that could value AMS at between £550 million and £600 million. According to banking sources, the buyout firm is looking at a bid price of 270p to 280p per share. This represents a significant premium of more than 30% over AMS's current share price, which was trading at around 208.5p on Friday morning, giving the company a market capitalisation of approximately £455 million.
As of Friday, 5 December 2025, it remained unclear whether Bridgepoint had made a formal approach to the board of AMS. Both companies have declined to comment on the speculation.
A History of Private Equity Interest
This is not the first time AMS has attracted the attention of private equity investors. The news of Bridgepoint's interest follows months after Montagu Private Equity walked away from a potential bid for the company. Furthermore, another firm, Inflexion Private Equity, was also reportedly studying a potential offer for AMS last year.
AMS Group, which is listed on London's junior AIM stock market, manufactures well-known surgical brands such as LiquiBand and Resorba. The company demonstrated strong financial performance in its most recent update, reporting a 49% rise in pre-tax profit in its interim results released in September.
Market Context and Future Implications
The potential bid highlights continued private equity appetite for stable, specialist healthcare businesses. Despite its robust profit growth, AMS's share price has been broadly flat over the past year, potentially making it an attractive target for investors seeking value.
If the offer proceeds, it would mark one of the more significant private equity moves in the UK medical technology space this year. The deal would see Bridgepoint add a established portfolio of surgical products to its investments, which span various sectors including consumer, financial, and business services.
The development underscores the ongoing consolidation trend within the healthcare supply sector, as larger firms and financial investors seek to capitalise on innovative medical technologies and brands with strong market positions.
